ofF-pump veRsus on-pump coronAry-artery bypass GraftIng in fragiLe patiEnts (FRAGILE)

• Grant number: 15/23972-3
• Support Opportunities: Research Projects - Thematic Grants
• Start date: January 01, 2018
• End date: December 31, 2024
• Field of knowledge: Health Sciences - Medicine - Surgery
• Principal Investigator: Fabio Biscegli Jatene
• Grantee: Fabio Biscegli Jatene
• Host Institution: Instituto do Coração Professor Euryclides de Jesus Zerbini (INCOR). Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
• Pesquisadores principais: Omar Asdrúbal Vilca Mejía
• Associated researchers: Bianca Correa Meneghini ; John Puskas ; Luis Alberto Oliveira Dallan ; Luiz Augusto Ferreira Lisboa ; Omar Asdrúbal Vilca Mejía
• Associated scholarship(s): 24/06456-0 - Database acquisition and monitoring., BP.TT; 22/01168-1 - Quality of life assessment in frail patients undergoing off-pump versus on-pump coronary artery bypass graft surgery, BP.IC; 22/01169-8 - Assessment of renal function in fragile patients undergoing off-pump and on-pump coronary artery bypass graft surgery, BP.IC

Abstract

Advances in modern Medicine have led to people living longer and healthier lives. Fragile is an emerging concept in Medicine yet to be explored as a risk factor in cardiac surgery. The optimize surgical myocardial revascularization to all clinical scenarios, compare Off-Pump Coronary Artery Bypass graft (OPCAB) versus on-pump Coronary Artery Bypass Graft (CABG), not yet unveiled. In this context, the randomized, controlled clinical trials so far have primarily focused only on low-risk (ROOBY, CORONARY), elevated-risk (GOPCABE) or high-risk patients (BBS) but not in fragile patients. Medicine advancing a new approach that makes health care more predictive, preventive, participatory, and mainly personalized. Therefore, we believe OPCAB could be an important technique in patients with limited functional capacity to respond to surgical stress. In this study, the authors introduce a national, multicentre, randomized, controlled trial "fragile" to be developed in the main cardiac surgery centers of Brazil, to clarify the potential benefit of OPCAB in fragile patients. (AU)